Clinical Trial: Efficacy and Safety of Low-dose IL-2 in SLE Patients With CMV Viremia

U.S., May 15 -- ClinicalTrials.gov registry received information related to the study (NCT06971913) titled 'Efficacy and Safety of Low-dose IL-2 in SLE Patients With CMV Viremia' on Feb. 18.

Brief Summary: This clinical trial will assess the efficacy and safety of low-dose interleukin-2 (IL-2) treatment in systemic lupus erythematosus (SLE) complicated with cytomegalovirus (CMV) viremia.

Study Start Date: May 20

Study Type: INTERVENTIONAL

Condition: SLE (Systemic Lupus) CMV

Intervention: DRUG: Interleukin-2 (IL-2)

Low-dose IL-2 at 1MIU will be administered subcutaneously every other day from baseline to CMV negativity.

DRUG: Ganciclovir (GCV)

Ganciclovir injection will be administrated intravenously at a dose of 5mg/kg per day.

R...